These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18042935)

  • 1. Re: Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.
    Ponti A; Rosso S; Zanetti R; Ricceri F; Tomatis M; Segnan N
    J Natl Cancer Inst; 2007 Dec; 99(23):1817-8; author reply 1819. PubMed ID: 18042935
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population.
    Anderson BO
    J Natl Cancer Inst; 2007 Dec; 99(23):1815-6; author reply 1816-7. PubMed ID: 18042937
    [No Abstract]   [Full Text] [Related]  

  • 3. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.
    Glass AG; Lacey JV; Carreon JD; Hoover RN
    J Natl Cancer Inst; 2007 Aug; 99(15):1152-61. PubMed ID: 17652280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.
    Chu DZ
    J Natl Cancer Inst; 2008 Apr; 100(8):596-7. PubMed ID: 18398103
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population.
    Robbins AS; Clarke CA
    J Natl Cancer Inst; 2007 Dec; 99(23):1815; author reply 1816-7. PubMed ID: 18042938
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.
    Byers T; Trujillo S; Hines L
    J Natl Cancer Inst; 2008 Apr; 100(8):596. PubMed ID: 18398102
    [No Abstract]   [Full Text] [Related]  

  • 7. Hormone therapy use and breast cancer incidence by histological subtypes in Sweden and Norway.
    Suhrke P; Mæhlen J; Zahl PH
    Breast J; 2012; 18(6):549-56. PubMed ID: 23002918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population.
    Caan B; Habel L; Quesenberry C; Kushi L; Herrinton L
    J Natl Cancer Inst; 2008 Apr; 100(8):597-8; author reply 599. PubMed ID: 18398101
    [No Abstract]   [Full Text] [Related]  

  • 9. In situ breast cancer: incidence trend and organised screening programmes in Italy.
    Barchielli A; Federico M; De Lisi V; Bucchi L; Ferretti S; Paci E; Ponti A; Buiatti E
    Eur J Cancer; 2005 May; 41(7):1045-50. PubMed ID: 15862754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Breast cancer screening in the elderly].
    Amodeo C; Caglià P; Gandolfo L; Veroux M; Brancato G; Immè A
    Tumori; 2003; 89(4 Suppl):173-4. PubMed ID: 12903582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening and detection of breast cancer and prostate cancer.
    Saloustros E; Mavroudis D
    JAMA; 2010 Mar; 303(11):1032; author reply 1033-4. PubMed ID: 20233817
    [No Abstract]   [Full Text] [Related]  

  • 12. Overdiagnosis of breast cancer after 14 years of mammography screening.
    Zahl PH; Mæhlen J
    Tidsskr Nor Laegeforen; 2012 Feb; 132(4):414-7. PubMed ID: 22353833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population-based mammography screening and breast cancer incidence in New South Wales, Australia.
    Chiu C; Morrell S; Page A; Rickard M; Brassil A; Taylor R
    Cancer Causes Control; 2006 Mar; 17(2):153-60. PubMed ID: 16425093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical-biological meaning of progesterone receptor status in 118 estrogen receptor positive infiltrating ductal carcinomas of the breast in post-menopausal women].
    Ruibal A; Schneider J; Arias J; del Río MC; Núnez MJ; Tejerina A
    Rev Esp Med Nucl; 2000 Jun; 19(3):244-6. PubMed ID: 11062090
    [No Abstract]   [Full Text] [Related]  

  • 15. Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy use.
    Farhat GN; Walker R; Buist DS; Onega T; Kerlikowske K
    J Clin Oncol; 2010 Dec; 28(35):5140-6. PubMed ID: 21060026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting risk of breast cancer in postmenopausal women by hormone receptor status.
    Chlebowski RT; Anderson GL; Lane DS; Aragaki AK; Rohan T; Yasmeen S; Sarto G; Rosenberg CA; Hubbell FA;
    J Natl Cancer Inst; 2007 Nov; 99(22):1695-705. PubMed ID: 18000216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of invasive breast cancer and ductal carcinoma in situ in a screening program by age: should older women continue screening?
    Erbas B; Amos A; Fletcher A; Kavanagh AM; Gertig DM
    Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1569-73. PubMed ID: 15466971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population.
    Vaidya JS
    J Natl Cancer Inst; 2008 Apr; 100(8):598-9; author reply 599. PubMed ID: 18398100
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
    Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
    Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population.
    Kerlikowske K; Miglioretti DL; Buist DS; Walker R; Carney PA;
    J Natl Cancer Inst; 2007 Sep; 99(17):1335-9. PubMed ID: 17698950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.